APA (7th ed.) Citation

Hargrave, D. R., Terashima, K., Hara, J., Kordes, U. R., Upadhyaya, S. A., Sahm, F., . . . Cohen, K. J. (2023). Phase II trial of dabrafenib plus trametinib in relapsed/refractory BRAF V600-mutant pediatric high-grade glioma. Journal of clinical oncology, 41(33), . https://doi.org/10.1200/JCO.23.00558

Chicago Style (17th ed.) Citation

Hargrave, Darren R., et al. "Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/refractory BRAF V600-mutant Pediatric High-grade Glioma." Journal of Clinical Oncology 41, no. 33 (2023). https://doi.org/10.1200/JCO.23.00558.

MLA (9th ed.) Citation

Hargrave, Darren R., et al. "Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/refractory BRAF V600-mutant Pediatric High-grade Glioma." Journal of Clinical Oncology, vol. 41, no. 33, 2023, https://doi.org/10.1200/JCO.23.00558.